Microbiome and its role in bronchiectasis
Therapeutic Advances in Respiratory Disease · 2026-04 · 20
DOI: 10.1177/17534666261444168 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 29.04.2026. Verfasst von Yiting Pan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Bronchiectasis, Dysbiosis, Microbiota, Lung. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Noncommunicable Chronic DiseasesNational Science and Technology Major Project, National Natural Science Foundation of China, Major Project of Guangzhou National Laboratory.
Abstract (Originalsprache)
Bronchiectasis (BE) is a chronic respiratory disease characterized by damage to the bronchial wall structure and permanent dilation of the bronchi. The symptoms include a persistent cough, excessive production of purulent sputum, and recurrent hemoptysis. Dysbiosis of the microbiome plays a crucial role in the progression of BE. An increased abundance of pathogenic bacteria, along with viral and fungal infections, is closely associated with disease severity and clinical outcomes. Next-generation sequencing technology has significantly enhanced the sensitivity and resolution of the airway microbiome, providing powerful tools for a more detailed characterization of the microecology of BE. However, certain challenges still exist in clinical applications of this technology. In addition, extra-airway microbiomes, such as the gut and oral microbiome, may participate in airway inflammation and immune regulation through the gut-lung axis and oral-lung axis. In this review, we summarize the characteristics of microbiome dysbiosis in BE and highlight the potential value of related biomarkers in disease classification, severity assessment, and prognosis. We also provide an overview of recent treatment advancements. A deeper understanding of the microbiome’s role in BE may facilitate early diagnosis and the optimization of individualized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai, China.
- Department of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China.
- Department of Respiratory and Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
ORCID-Profile: Yiting Pan, Jin-Fu Xu
Förderung
- Noncommunicable Chronic DiseasesNational Science and Technology Major Project
- National Natural Science Foundation of China
- Major Project of Guangzhou National Laboratory
- Innovation Program of Shanghai Municipal Education Commission
Zitieren
APA
Pan, Y., & Xu, J. F. (2026). Microbiome and its role in bronchiectasis. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261444168
Vancouver
Pan Y, Xu JF. Microbiome and its role in bronchiectasis. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261444168
BibTeX
@article{Pan2026,
author = {Pan, Yiting and Xu, Jin-Fu},
title = {Microbiome and its role in bronchiectasis},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2026},
volume = {20},
doi = {10.1177/17534666261444168}
}
EUVIMED